A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects
This study has been terminated.
(Termination is due to a combination of a device defect potentially impacting the quality of the AD 923 IMP and a major change in corporate strategy.)
Information provided by:
First received: March 4, 2008
Last updated: June 5, 2008
Last verified: June 2008
The purpose of this study is to compare the efficacy and safety of AD 923 to the most widely used current treatment (MSIR) in the management of target BTP in subjects with malignancies who are taking a stable dose of background opioids. The efficacy evaluation criteria have been designed to determine whether AD 923 provides superior analgesia compared with MSIR as measured by the primary endpoint.
Drug: AD 923
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
||A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects With Malignancies
Primary Outcome Measures:
- To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignancies who are taking a stable dose of background opioids.
Secondary Outcome Measures:
- To assess the safety and tolerability of AD 923 in the management of breakthrough pain in subjects with malignancies who are taking a stable dose of background opioids.
| Estimated Enrollment:
| Study Start Date:
Experimental: AD 923
Drug: AD 923
Active Comparator: MSIR
Drug: AD 923
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Main Inclusion Criteria:
- The subject is a male or female, at least 18 years of age.
- The subject has a malignancy, is receiving opioid therapy for his or her underlying persistent cancer pain, and is tolerant to the opioid therapy.
- The subject typically has 2 to 6 episodes of target BTP per day that require treatment.
- The subject has a life expectancy of >3 months.
- The subject or his or her caregiver has easy, reliable access to a telephone.
Main Exclusion Criteria:
- The subject is a female who is pregnant or lactating.
- The subject has any respiratory or cardiac condition that, in the opinion of the investigator, may be clinically worsened by opioids.
- The subject has any allergy to the AD 923 product or excipients, namely: fentanyl, dehydrated alcohol, menthol, saccharin, and citrate buffer; or to the MSIR product excipients, namely: morphine sulphate, lactose (anhydrous), pregelatinized maize starch, povidone, purified water, magnesium stearate, talc, and tablet coatings.
- The subject has any neurological or psychiatric disease that, in the opinion of the investigator, would compromise data collection.
- The subject has uncontrolled or rapidly escalating pain.
- The subject has any significant laboratory test results that, in the opinion of the investigator, will compromise subject safety or the conduct of the study.
- The subject has plans to undergo chemotherapy, radiotherapy, or surgery during the treatment period. The exception is that subjects may continue chemotherapy over the study period, provided it is not expected to alter the pain state or response to pain medication.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00635063
|Sosei R&D Ltd
|Saffron Walden, Essex, United Kingdom, CB10 1XL |
||Andrew Davies, MBBS
||Royal Marsden NHS Foundation Trust
No publications provided
||Dr Robin Bannister, Sosei R&D Ltd
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 4, 2008
||June 5, 2008
||United Kingdom: Medicines and Healthcare Products Regulatory Agency
Belgium: Federal Agency for Medicinal Products and Health Products
Romania: National Medicines Agency
Spain: Spanish Agency of Medicines
Netherlands: Medicines Evaluation Board (MEB)
Keywords provided by Sosei:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 27, 2015
Nervous System Diseases
Signs and Symptoms